1Department of Clinical Research Design & Evaluation, SAIHST, Sungkyunkwan University, Seoul, Korea
2Center for Clinical Epidemiology, Samsung Medical Center, Seoul, Korea
3National Cancer Survivorship Center, National Cancer Control Institute, National Cancer Center, Goyang, Korea
4Patient-Centered Outcomes Research Institute, Samsung Medical Center, Seoul, Korea
5Cancer Education Center, Samsung Medical Center, Seoul, Korea
6Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
7Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
8Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
9Department of Surgery, Ajou University School of Medicine, Suwon, Korea
10Department of Radiation Oncology, Ajou University School of Medicine, Suwon, Korea
Copyright © 2023 by the Korean Cancer Association
This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Ethical Statement
The study was approved by the Institutional Review Board of the Samsung Medical Center (No. SMC 2018-08-034) and Ajou University Medical Center (No. AJIRB-MED-SUR-18-375). All study participants provided written informed consent.
Author Contributions
Conceived and designed the analysis: Kang D, Cho J.
Collected the data: Bae KR, Ahn Y, Kim N, Nam SJ, Lee JE, Lee SK, Shim YM, Shin DH, Oh SY, Chun M, Heo J, Cho J.
Contributed data or analysis tools: Nam SJ, Lee JE, Lee SK, Shim YM, Shin DH, Oh SY, Chun M, Heo J.
Performed the analysis: Kang D.
Wrote the paper: Kang D, Bae KR, Ahn Y, Cho J.
Conflicts of Interest
Conflict of interest relevant to this article was not reported.
Participants returning to work, n (%) | Control vs. intervention OR (95% CI)b) | |||
---|---|---|---|---|
Intervention (n=101) | Control (n=111) | p-valueb) | ||
Return to work | ||||
Overall | ||||
End of intervention (n=196) | 54 (63.5) | 61 (55.0) | 0.060 | 1.81 (0.97–3.36) |
1 Month after intervention (n=212) | 66 (65.4) | 62 (55.9) | 0.037 | 1.88 (1.04–3.39) |
Patients without job at baseline | ||||
End of intervention (n=152) | 41 (57.8) | 35 (43.2) | 0.075 | 1.79 (0.94–3.42) |
1 Month after intervention (n=164) | 51 (60.7) | 35 (43.8) | 0.030 | 1.99 (1.07–3.70) |
Patients with job at baseline | ||||
End of intervention (n=44) | 13 (92.9) | 26 (86.7) | 0.553 | 2.00 (0.20–19.75) |
1 Month after intervention (n=42) | 15 (88.2) | 27 (87.1) | 0.909 | 1.37 (0.61–3.06) |
Specific plan for returning to work | ||||
Overall | ||||
End of intervention (n=81) | 25 (80.7) | 33 (66.0) | 0.174 | 2.10 (0.72–6.13) |
1 Month after intervention (n=84) | 66 (65.4) | 62 (55.9) | 0.522 | 0.75 (0.30–1.83) |
Patients without job at baseline | ||||
End of intervention (n=76) | 24 (80.0) | 31 (67.4) | 0.234 | 1.94 (0.65–5.74) |
1 Month after intervention (n=78) | 20 (60.6) | 29 (64.4) | 0.729 | 1.95 (0.65–5.74) |
Patients with job at baseline | ||||
End of intervention (n=5) | 1 (100) | 2 (50.0) | > 0.999 | - |
1 Month after intervention (n=6) | 0 | 2 (50.0) | > 0.999 | - |
Participants returning to work, n (%) | Control vs. intervention OR (95% CI)b) | |||
---|---|---|---|---|
Intervention (n=78) | Control (n=103) | p-valueb) | ||
Overall | 63 (80.8) | 78 (75.7) | 0.188 | 1.65 (0.78–3.48) |
Patients without job at baseline | 51 (77.3) | 51 (68.0) | 0.221 | 1.60 (0.75–3.40) |
Patients with job at baseline | 0 | 2 (50.0) | > 0.999 | - |
Intervention (n=120) | Control (n=119) | p-value | |
---|---|---|---|
Age (yr) | 48.6±9.0 | 50.5±8.7 | 0.110 |
Sex | |||
Male | 37 (30.8) | 34 (28.6) | 0.702 |
Female | 83 (69.2) | 85 (71.4) | |
Marital status (n=238) | |||
Married | 26 (21.7) | 25 (21.2) | 0.928 |
Unmarried | 94 (78.3) | 93 (78.8) | |
Education (n=238) | |||
< College | 42 (35.0) | 40 (33.9) | 0.858 |
≥ College | 78 (65.0) | 78 (66.1) | |
Monthly family income (n=235) | |||
< $ 5,000 | 53 (44.9) | 59 (50.4) | 0.398 |
≥ $5,000 | 65 (55.1) | 58 (49.6) | |
Type of job | |||
Permanent position | 62 (51.7) | 57 (47.9) | 0.927 |
Temporarily position | 27 (22.5) | 27 (22.7) | |
Self-business | 29 (24.2) | 33 (27.7) | |
Others | 2 (1.7) | 2 (1.7) | |
Working status | |||
Continued working | 21 (17.5) | 34 (28.6) | 0.042 |
No work | 99 (82.5) | 85 (71.4) | |
Sick leave | 67 (55.8) | 63 (52.9) | |
Leave of absence | 18 (15.0) | 16 (13.5) | |
Resignation | 14 (11.7) | 6 (5.0) | |
Competency for the work | |||
Physical | 46 (38.3) | 49 (41.2) | 0.893 |
Mental | 13 (10.8) | 13 (10.9) | |
Both | 61 (50.8) | 57 (47.9) | |
Type of cancer | |||
Breast | 73 (60.8) | 72 (60.5) | 0.975 |
Lung | 25 (20.8) | 24 (20.2) | |
Liver | 9 (7.5) | 8 (6.7) | |
Colon | 9 (7.5) | 9 (7.6) | |
Others | 4 (3.33) | 6 (5.0) | |
Stage | |||
0 | 18 (15.0) | 16 (13.5) | 0.764 |
I | 47 (39.2) | 54 (45.4) | |
II | 37 (30.8) | 35 (29.4) | |
III | 18 (15.0) | 14 (11.8) | |
Treatment modalities | |||
Chemotherapy | 48 (40.0) | 48 (40.3) | 0.958 |
Radiation therapy | 64 (53.3) | 54 (45.4) | 0.219 |
Hormone therapy | 57 (47.5) | 56 (47.1) | 0.946 |
Values were presented as mean±standard deviation or number (%).
Participants returning to work, n (%) | Control vs. intervention OR (95% CI) | |||
---|---|---|---|---|
Intervention (n=101) | Control (n=111) | p-value | ||
Return to work | ||||
Overall | ||||
End of intervention (n=196) | 54 (63.5) | 61 (55.0) | 0.060 | 1.81 (0.97–3.36) |
1 Month after intervention (n=212) | 66 (65.4) | 62 (55.9) | 0.037 | 1.88 (1.04–3.39) |
Patients without job at baseline | ||||
End of intervention (n=152) | 41 (57.8) | 35 (43.2) | 0.075 | 1.79 (0.94–3.42) |
1 Month after intervention (n=164) | 51 (60.7) | 35 (43.8) | 0.030 | 1.99 (1.07–3.70) |
Patients with job at baseline | ||||
End of intervention (n=44) | 13 (92.9) | 26 (86.7) | 0.553 | 2.00 (0.20–19.75) |
1 Month after intervention (n=42) | 15 (88.2) | 27 (87.1) | 0.909 | 1.37 (0.61–3.06) |
Specific plan for returning to work | ||||
Overall | ||||
End of intervention (n=81) | 25 (80.7) | 33 (66.0) | 0.174 | 2.10 (0.72–6.13) |
1 Month after intervention (n=84) | 66 (65.4) | 62 (55.9) | 0.522 | 0.75 (0.30–1.83) |
Patients without job at baseline | ||||
End of intervention (n=76) | 24 (80.0) | 31 (67.4) | 0.234 | 1.94 (0.65–5.74) |
1 Month after intervention (n=78) | 20 (60.6) | 29 (64.4) | 0.729 | 1.95 (0.65–5.74) |
Patients with job at baseline | ||||
End of intervention (n=5) | 1 (100) | 2 (50.0) | > 0.999 | - |
1 Month after intervention (n=6) | 0 | 2 (50.0) | > 0.999 | - |
CI, confidence interval; OR, odds ratio.
a)We excluded participants who had recurrence during follow-up (n=6),
b)Adjusted for baseline working status in overall participants.
Participants with correct knowledge | |||
---|---|---|---|
Intervention (n=85) | Control (n=111) | p-value | |
It is impossible to work during cancer treatment. (no) | 67 (79.8) | 68 (62.4) | 0.009 |
Cancer patients take at least a year off after treatment. (no) | 59 (69.4) | 66 (60.6) | 0.201 |
Diagnosis of cancer can be a reason for dismissal. (yes) | 74 (87.1) | 89 (81.7) | 0.308 |
Cancer patients could ask the company to adjust their working hours for treatment. (yes) | 57 (67.1) | 85 (76.6) | 0.139 |
Cancer patients could ask the company for sick leave during treatment. (yes) | 75 (89.3) | 102 (92.7) | 0.401 |
Working prevents patients’ recovery. (no) | 60 (70.6) | 71 (64.0) | 0.329 |
Cancer patients should not go out for dinner after work. (no) | 76 (90.5) | 91 (82.7) | 0.122 |
Stress at workplace increases the risk of cancer recurrence. (no) | 38 (44.7) | 29 (26.6) | 0.009 |
Cancer patients could return to a healthy state prior to diagnosis. (no) | 68 (80.0) | 73 (66.4) | 0.035 |
Cancer patients could regain the same work ability as before treatment post treatment. (no) | 56 (65.9) | 78 (70.3) | 0.513 |
Total score (0–10) | 7.4 (1.9) | 6.8 (2.1) | 0.029 |
Values are presented as number (%).
a)We excluded participants who had recurrence during follow-up (n=6).
Participants returning to work, n (%) | Control vs. intervention OR (95% CI) | |||
---|---|---|---|---|
Intervention (n=78) | Control (n=103) | p-value | ||
Overall | 63 (80.8) | 78 (75.7) | 0.188 | 1.65 (0.78–3.48) |
Patients without job at baseline | 51 (77.3) | 51 (68.0) | 0.221 | 1.60 (0.75–3.40) |
Patients with job at baseline | 0 | 2 (50.0) | > 0.999 | - |
CI, confidence interval; OR, odds ratio.
a)We excluded participants who had recurrence during follow-up (n=6),
b)Adjusted for baseline working status in overall participants.
Values were presented as mean±standard deviation or number (%).
CI, confidence interval; OR, odds ratio. We excluded participants who had recurrence during follow-up (n=6), Adjusted for baseline working status in overall participants.
Values are presented as number (%). We excluded participants who had recurrence during follow-up (n=6).
CI, confidence interval; OR, odds ratio. We excluded participants who had recurrence during follow-up (n=6), Adjusted for baseline working status in overall participants.